PPARγ regulates the mitochondrial dysfunction in human neural stem cells with tumor necrosis factor alpha

Area of Science:

• Neuroscience
• Molecular Biology
• Cell Biology

Background:

• Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated transcription factor involved in various physiological and pathological processes.
• Tumor necrosis factor alpha (TNFα) plays a role in neuronal impairment, potentially contributing to neurodegenerative diseases.

Purpose of the Study:

• To investigate whether the PPARγ agonist rosiglitazone can protect human neural stem cells (hNSCs) from TNFα-induced damage.
• To elucidate the mechanisms by which PPARγ influences TNFα-related neuronal impairment and mitochondrial function.

Main Methods:

• Treatment of hNSCs with rosiglitazone and TNFα.
• Assessment of cell viability, caspase 3 activity, and levels of AMPK and SIRT1.
• Analysis of mitochondrial function, oxidative defense, and the PGC1α pathway.
• Evaluation of protection against Aβ-induced apoptosis.

Main Results:

• Rosiglitazone mediated hNSC viability by downregulating caspase 3 activity.
• PPARγ activation improved reduced levels of AMPK and SIRT1 in TNFα-treated hNSCs.
• PPARγ stimulation enhanced mitochondrial function via the PGC1α pathway, up-regulating oxidative defense.
• Rosiglitazone protected hNSCs from TNFα-induced oxidative stress, mitochondrial deficiency, and Aβ-induced apoptosis.

Conclusions:

• PPARγ activation, specifically by rosiglitazone, confers significant protection to hNSCs against TNFα-induced impairment.
• The protective effects involve the restoration of mitochondrial function and anti-apoptotic mechanisms.
• These findings highlight the critical role of PPARγ in mitigating TNFα-related neuronal damage and suggest therapeutic potential for neurodegenerative diseases.